article thumbnail

Vertex pays CRISPR to use its gene editing tech for diabetes drugs

Bio Pharma Dive

Vertex will license CRISPR technology to develop insulin-producing islet cells that are more resistant to immune rejection, adding to other efforts directed at Type 1 diabetes.

article thumbnail

PAX5—a gene strongly associated with impaired insulin secretion in type 2 diabetes

Medical Xpress

Researchers have identified 395 genes that are differently expressed in people with type 2 diabetes. One of the genes proved to be very strongly associated with impaired insulin secretion. Now, researchers want to investigate if it is possible to use the genetic CRISPR/Cas9 scissors to correct the gene's activity.

Insulin 91
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cell culture Q&A: Solving biomanufacturing challenges with Recombinant Insulin supplementation

Pharmaceutical Technology

It is no exaggeration to say that the world changed in the early 80s when insulin was expressed synthetically in microorganisms for the first time. This breakthrough led to a recombinant (biosynthetic) and thereby safer therapy for diabetes than the animal-sourced insulin which had been used since 1922.

Insulin 130
article thumbnail

Understanding the role of recombinant insulin in cell culture systems: What the studies say 

Pharmaceutical Technology

Among several growth-promoting supplements added to the cell culture media formulations, insulin is one of the most common. Recombinant insulin is used as a supplement in the upstream manufacturing of a range of biologic drugs, including recombinant proteins, such as monoclonal antibodies, viral vectors, and viruses.

Insulin 130
article thumbnail

Newly Approved T1D Therapy Lantidra Could Eliminate Need for Insulin Injections

XTalks

Making for another landmark cell and gene therapy approval this month, the US Food and Drug Administration (FDA) has signed off on CellTrans’ Lantidra (donislecel), the first cell therapy for type 1 diabetes. Lantidra is thought to increase insulin secretion through the infusion of allogeneic insulin-producing islet beta cells.

Insulin 98
article thumbnail

Vertex signs licence deal with CRISPR Therapeutics for diabetes therapies

Pharmaceutical Technology

Under the terms of the deal, the company will receive non-exclusive rights to CRISPR/Cas9, a gene-editing technology of CRISPR Therapeutics, for the development of potentially curative T1D cell therapies. The gene-editing technology allows for precise, directed changes to genomic DNA.

article thumbnail

Vertex signs agreement to acquire ViaCyte for $320m

Pharmaceutical Technology

VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy of Vertex for T1D. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Through the acquisition, Vertex plans to advance its potentially curative VX-880 programmes in T1D.